A pan-cancer analysis of LSM2 expression using the GEPIA database revealed significantly higher expression of LSM2 in tumour samples compared to normal samples across various cancer types, including glioblastoma (GBM) and lower-grade glioma (LGG) (p < 0.05) (Figure 2A). The gene discussed is LSM2; the disease is glioma.